many patients will reach their goal on methotrexate monotherapy and because of the additional risks of toxicity and higher costs associated with TNF inhibitors. The recommendation is conditional because some patients, especially those with poor prognostic factors, may prioritize more rapid onset of action and greater chance of improvement associated with combination therapy Methotrexate monotherapy is strongly recommended over methotrexate plus a non-TNF inhibitor bDMARD or tsDMARD for